Max Robotics — Global Service Robot Directory + US Certification

About

Yosuke Mukai is a leading surgical oncologist whose research focuses on advanced gastric and rectal cancers, particularly through the lens of robotic surgery and targeted therapies. His work addresses critical challenges in treating aggressive malignancies, including the management of portal vein tumor thrombus (PVTT) in gastric cancer—a condition with notoriously poor prognosis. In a landmark 2022 study (10 citations), Mukai demonstrated the feasibility of a completely robotic total gastrectomy with thrombectomy and portal vein reconstruction, offering a minimally invasive alternative to highly morbid open laparotomies. He has also pioneered research on the learning curve for prophylactic bilateral robot-assisted lateral lymph node dissection (RA-LLND) for lower rectal cancer (2025, 3 citations), providing essential benchmarks for surgical training and adoption. Beyond the operating room, Mukai has made critical contributions to medical oncology, reporting the first real-world cases of protein-losing enteropathy induced by zolbetuximab—a novel CLDN18.2-targeted therapy—in patients with advanced gastric cancer (2025, 13 citations). This work, emerging from the GLOW and SPOTLIGHT trials, underscores his commitment to translating clinical trial findings into safer, more effective patient care. With a career bridging innovative surgical techniques and precision oncology, Mukai continues to shape the future of gastrointestinal cancer treatment.